Matthew Davids, MD, MMSc, of the Dana-Farber Cancer Institute, discusses ZUMA-8 results during the 2022 Annual American Society of Hematology Meeting. The trial evaluated brexucabtagene autoleucel in patients with heavily pretreated chronic lymphocytic leukemia.
Matthew Davids, MD, MMSc, Discusses ZUMA-8 at ASH
By Cecilia Brown, Matthew Davids, MD, MMSc - Last Updated: January 11, 2023Post Tags:AML ASH 22
Related Posts
In a narrative review Dr. Krina Patel participated in and describes in this interview, myeloma experts engaged this question.
Dr. Ryan Jacobs reviews the latest CLL data, highlighting time-limited regimens, BTK combos, and clinical trial updates.
Side effects are an important consideration when using bispecific antibodies in this population, Dr. Krina Patel explains.
The phase 3 SENTRY trial will randomize patients to ruxolitinib plus placebo or selinexor plus placebo.
Dr. Krina Patel was part of a comparative study team which evaluated these two therapies' efficacy and safety in MM care.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.